Stay updated on DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial

Sign up to get notified when there's something new on the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.8%
    Check dated 2025-07-04T04:10:24.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.6%
    Check dated 2025-06-19T20:05:05.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:24:43.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, and API users can provide input before this change. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T06:11:19.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T16:52:50.000Z thumbnail image
  8. Check
    77 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates regarding a Phase 1b clinical study involving DS-8201a and pembrolizumab for advanced breast cancer and NSCLC, with new identifiers and collaborators added, while extensive details about the study's design and inclusion criteria have been removed.
    Difference
    32%
    Check dated 2025-04-23T15:33:15.000Z thumbnail image

Stay in the know with updates to DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the DS8201a and Pembrolizumab in Advanced Cancer Clinical Trial page.